VK
Viswanath Kodukula
About Viswanath Kodukula
Viswanath Kodukula has 6 years in corporate governance. Holds Director and Additional Director roles. Currently with 4 companies, including Ivok Pluitech Private Limited and Neubay Ai Private Limited. Formerly with 1 company. Engaged in Technology, General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Ivok Pluitech Private Limited
U74110TG2021PTC151165
|
Director | 27 Apr 2022 | 2021 | Active |
Biocytica Technologies Private Limited
U72100TS2025PTC207232
|
Director | 06 Dec 2025 | 2025 | Active |
Npo Consulting Llp
ACF-1389
|
Designated Partner | 25 Mar 2025 | 2024 | Active |
B5 Corporation Private Limited
U70200TG2007PTC056164
|
Director | 09 Jan 2025 | 2007 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Neubay Ai Private Limited
U72900TG2018FTC127797
|
Additional Director | 10 Aug 2019 | 2018 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Viswanath Kodukula
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viswanath Kodukula
Viswanath Kodukula has 6 years in corporate governance. Holds Director and Additional Director roles. Currently with 4 companies, including Ivok Pluitech Private Limited and Neubay Ai Private Limited. Formerly with 1 company. Engaged in Technology, General Business. Contributes to corporate operations.
Viswanath Kodukula is associated with 4 companies as Director and Additional Director.
Viswanath Kodukula has expertise in Technology, General Business.
Viswanath Kodukula has 6 years in corporate governance.